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Alemtuzumab is a humanized monoclonal anti-
body licensed in over 60 countries for the treat-
ment of patients with relapsing-remitting multiple 
sclerosis (RRMS). The efficacy and safety of two 
annual courses of alemtuzumab 12 mg were eval-
uated in three randomized, head-to-head, rater-
blinded, clinical trials against subcutaneous (SC) 
interferon (IFN)β-1a 44 μg three times per week 
in patients with active RRMS. Overall, two of the 
trials included patients who were treatment-naïve 
(phase II CAMMS223 study [ClinicalTrials.gov 
identifier: NCT00050778] and phase III 
Comparison of Alemtuzumab and Rebif® Efficacy 
in Multiple Sclerosis [CARE-MS I; ClinicalTrials.
gov identifier: NCT00530348]), whereas the 
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Abstract: Alemtuzumab is a humanized monoclonal antibody approved for the treatment 
of relapsing-remitting multiple sclerosis (RRMS), given as two annual courses on five 
consecutive days at baseline and on three consecutive days 12 months later. Here we provide 
an update on the long-term efficacy and safety of alemtuzumab in RRMS, including real-
world experience, and advances in our understanding of its mechanism of action. Recent data 
from the phase II/III extension study have demonstrated that alemtuzumab reduces relapse 
rates, disability worsening, and the rate of brain volume loss over the long term, with many 
patients achieving no evidence of disease activity. In high proportions of patients, preexisting 
disability remained stable or improved. Alemtuzumab is associated with a consistent safety 
profile over the long term, with no new safety signals emerging and the overall annual 
incidence of reported adverse events decreasing after the first year on treatment. Acyclovir 
prophylaxis reduces herpetic infections, and monitoring has been shown to mitigate the risk 
of autoimmune adverse events, allowing early detection and overall effective management. 
Data from clinical practice and ongoing observational studies are providing additional 
information on the real-world use of alemtuzumab. Recent evidence on the mechanism of 
action of alemtuzumab indicates that in addition to its previously known effects of inducing 
depletion and repopulation of T and B lymphocytes, it also results in a relative increase of 
cells with memory and regulatory phenotypes and a decrease in cells with a proinflammatory 
signature, and may further promote an immunoregulatory environment through an impact on 
other innate immune cells (e.g. dendritic cells) that play a role in MS. These effects may allow 
preservation of innate immunity and immunosurveillance. Together, these lines of evidence 
help explain the durable clinical efficacy of alemtuzumab, in the absence of continuous 
treatment, in patients with RRMS.
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third study included patients who had an inade-
quate response to prior therapy (phase III 
CARE-MS II [ClinicalTrials.gov identifier: 
NCT00548405]).1–3 Alemtuzumab significantly 
reduced relapses by 49−74% compared with SC 
IFNβ-1a (p < 0.001 in all studies), and signifi-
cantly reduced confirmed disability worsening 
(CDW) in the CAMMS223 (hazard ratio, 0.29; 
p < 0.001) and CARE-MS II trials (hazard ratio, 
0.58; p = 0.008). Patients in CARE-MS I dem-
onstrated a nonsignificant 30% reduction in risk 
of CDW (hazard ratio, 0.70; p = 0.22). In addi-
tion to these endpoints, alemtuzumab improved 
preexisting disability and reduced the rate of 
brain volume loss (BVL), with many patients 
achieving no evidence of disease activity (NEDA) 
on an annual basis. The long-term efficacy and 
safety of alemtuzumab were investigated in an 
extension of these clinical trials [ClinicalTrials.
gov identifier: NCT00930553], demonstrating 
durable efficacy with no new safety signals.4,5 The 
most common adverse events (AEs) in alemtu-
zumab clinical studies were infusion-associated 
reactions (IARs).1–3 Autoimmune AEs, most 
commonly affecting the thyroid, but with infre-
quent cases of immune thrombocytopenia (ITP), 
nephropathies, and infections, were also reported. 
Autoimmune events can generally be managed 
with active monitoring for early detection and 
prompt clinical attention.6,7
The dosing schedule for alemtuzumab, two 
courses comprising intravenous infusion of 12 
mg/day on five consecutive days at baseline and 
three consecutive days 12 months later (96 mg 
total dose), is distinct from other MS thera-
pies.6,8–10 In the clinical trials, additional treat-
ment courses of 12 mg/day on three consecutive 
days could be administered at least 12 months 
after the prior course upon documented evidence 
of MS disease activity and per discretion of the 
treating physician; however, many patients did 
not receive any additional treatment after the ini-
tial two courses of alemtuzumab. In contrast with 
other disease-modifying therapies (DMTs) 
approved for RRMS, which require dosing either 
daily, every other day, thrice weekly, weekly, 
every other week, monthly, or every 6 months, 
alemtuzumab is the only approved treatment that 
does not require regular dosing in RRMS patients.
With newly available data from the CARE-MS 
extension study, and several years of post-
approval, real-world use, our understanding of 
alemtuzumab’s long-term effects is increasing. 
This article reviews the evidence for long-term 
efficacy and safety of alemtuzumab, presents the 
data from real-world experience, and discusses 
advances in our understanding of the mechanism 
of action of alemtuzumab in RRMS. Up to know, 
13.000 MS patients have been treated with 
alemtuzumab.
Efficacy in long-term clinical trials
Study enrollment, retention, and alemtuzumab 
retreatment rates
Patients who completed the core phase II and III 
studies were eligible to enroll in a long-term 
extension study in which they could receive as-
needed retreatment with alemtuzumab, as deter-
mined by the treating physician in consultation 
with the patient. In order to receive alemtuzumab 
retreatment, patients were required to meet spe-
cific disease activity criteria: ⩾1 protocol-defined 
relapse, or ⩾2 new/enlarging T2 hyperintense or 
new gadolinium (Gd)-enhancing T1 brain or spi-
nal cord lesions on magnetic resonance imaging 
(MRI), and have none of the prespecified dis-
qualifications for retreatment (mainly pregnancy, 
malignancy, certain infections, and autoimmune 
conditions). Other DMTs could be administered 
at the investigator’s discretion.11 Alemtuzumab 
retreatment was unavailable for part of the 
CAMMS223 study follow up during a dosing 
suspension (2005−2008).
For the CARE-MS studies, data are available for 
6 years of treatment (2 years of the core study plus 
4 years of the extension). In CARE-MS I, 376 
patients were treated with alemtuzumab in the 
core study, 349 entered the extension, and 325 
remained on study through Year 6, for a retention 
rate of 86% from core study baseline and 93% 
from enrollment in the extension. In CARE-MS 
II, 435 patients were treated with alemtuzumab in 
the core study, 393 entered the extension, and 
344 remained on study through Year 6, with 
retention rates of 79% from core study baseline 
and 88% from extension study baseline.4,5
The CARE-MS study retention rates are higher 
than those reported for other DMTs after long-
term follow up over 4–5 years. For patients on 
fingolimod in the TRANSFORMS extension 
study, retention was 62% (526/849) from the 
core study baseline and 77% (526/687) from the 
extension study baseline12; the FREEDOMS 
extension study showed 63% (535/854) and 
86% (535/620) retention, respectively.13 In 
ENDORSE, for patients on dimethyl fumarate, 
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retention rates were 47% (720/1530) from core 
study baseline and 72% (720/1003) from exten-
sion study baseline.14–16 Loss to follow up in ran-
domized controlled trials may bias results if 
unavailable data are associated with the likeli-
hood of outcome events, and lead to both over- 
and under-estimation of treatment effects.17 The 
high retention rate of the CARE-MS extension 
study suggests that the long-term efficacy data 
for alemtuzumab are unusually robust compared 
with data from trials of other DMTs with higher 
dropout rates.
For the CAMMS223 study, patients completing 
the 3-year core study could enter an extended 
follow-up period (minimum additional 2 years), 
and then in 2010 they could enroll in the same 
extension study as patients from the CARE-MS 
studies, for a total available follow up of 10 years. 
Of the 108 patients who received alemtuzumab 
12 mg in CAMMS223, 92 completed the core 
study, 72 entered the extended follow-up period, 
and 60 patients entered the CARE-MS exten-
sion; 57 remained on study at Year 10.18
Many patients from the randomized controlled 
trials did not receive additional alemtuzumab 
during the extension (Figure 1). In CARE-MS I, 
64% of patients required only the initial two 
courses of alemtuzumab, with 23%, 8%, 3%, and 
<1% receiving a third, fourth, fifth, or sixth 
course, respectively, over 6 years.4 Similarly, in 
CARE-MS II, 55% of patients required only the 
initial two courses of alemtuzumab with 30%, 
12%, 2%, and 1% receiving a third, fourth, fifth, 
or sixth course, respectively.5 Of the patients from 
CAMMS223 who entered the CARE-MS exten-
sion, 33% received only the initial two courses of 
alemtuzumab over 10 years; 43%, 12%, and 10% 
received three, four, or five courses of alemtu-
zumab, respectively.18 Across the three studies, 
investigators cited relapse as the most common 
reason for retreatment.
Annualized relapse rate (ARR)
Relapse reduction with alemtuzumab was durable 
over the long term in the CARE-MS extension 
(Table 1). For patients from CARE-MS I, ARR 
Figure 1. Through Year 6 of the CARE-MS extension, in cohorts of patients entering from (a) CARE-MS I and 
(b) CARE-MS II, the majority of patients received no further alemtuzumab after their second course.4,5
CARE-MS, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; DMT, disease-modifying therapy; MRI, 
magnetic resonance imaging.
Therapeutic Advances in Neurological Disorders 10(10)
346 journals.sagepub.com/home/tan
was 0.16 during the randomized, controlled por-
tion of the trial (Years 0−2) and 0.15 at the end of 
the extension portion (Years 3−6); for patients 
from CARE-MS II, ARR was 0.28 and 0.20 in 
these time intervals, respectively.4,5 Among 
patients originating from the CAMMS223 study, 
an ARR of 0.07 in the core study (Year 3) was 
maintained through Year 10 (0.08).18
Disability
At Year 2, 85−89% of patients in the CARE-MS 
studies had stable [⩽0.5-point Expanded Disability 
Status Scale (EDSS) change from baseline] or 
improved (⩾1.0-point decrease from baseline) dis-
ability; whereas at Year 6, 77−81% of patients had 
stable or improved disability.4,5,19 Through Year 6, 
72−77% of patients were free of 6-month CDW 
[defined as an increase of ⩾1.0 EDSS point (or 
⩾1.5 points if baseline EDSS = 0)], and 34−43% 
of patients achieved 6-month confirmed disability 
improvement (CDI; defined as ⩾1-point EDSS 
decrease from baseline, assessed in patients with 
baseline score ⩾2.0; Figure 2).4,5 The proportion 
of patients with CDI increased from Year 2 to 
Year 6, indicating that patients continued to expe-
rience CDI events during the extension study. 
Furthermore, of the patients who achieved 
6-month CDI, 91−94% were free from 6-month 
CDW, indicating that the improvement in disabil-
ity was not followed by worsening.
Patients from CAMMS223 demonstrated that 
alemtuzumab stabilized disability over a 10-year 
timeframe. The mean EDSS score change from 
baseline to Year 10 (standard deviation) was 
+0.12 (1.4); disability scores remained stable or 
improved in 78% of alemtuzumab-treated 
patients, and most patients (76%) remained free 
of 6-month CDW through 10 years.18
An analysis of CARE-MS I and II estimated the 
proportion of patients who converted from RRMS 
to secondary progressive MS (SPMS) following 
alemtuzumab treatment, using a definition of 
SPMS recently developed by Lorscheider and 
colleagues based on data from the MSBase regis-
try.20,21 Low rates of conversion were observed 
over 6 years in CARE-MS I (1.1%) and 
CARE-MS II (3.7%).21 Notably, the rate of 
SPMS conversion among the MSBase cohort was 
18% over 5.8 years’ follow up.20
MRI lesions
In the CARE-MS studies, freedom from MRI 
disease activity was defined as an absence of new 
Gd-enhancing lesions and new/enlarging T2 
hyperintense lesions. In CARE-MS I, 77% of 
patients were free of MRI disease activity in Year 
2, and this effect was durable in Years 3−6, dur-
ing which 66−72% of patients were free of MRI 
disease activity in each year. MRI disease activity 
was driven by T2 hyperintense lesions, as the pro-
portion of patients without new Gd-enhancing 
lesions on their annual scan consistently remained 
near 90% in each year (range over Years 3−6: 
87−90%, compared with 93% in Year 2). 
Table 1. Key outcomes at completion of core study (Year 2) and CARE-MS Extension (Year 6).
Endpoint CARE-MS I CARE-MS II
Year 2 Year 6 Year 2 Year 6
ARRa 0.16 0.15 0.28 0.20
CDW-free (%) 92 77 89 72
EDSS improved/stable (%) 89 81 85 77
NEDA (annual) (%) 68 57 58 60
 Clinical disease activity-free (%) 85 86 73 85
 MRI disease activity-free (%) 77 66 76 69
  New T2 lesion-free (%) 78 67 76 69
  New Gd-enhancing lesion-free (%) 93 87 91 91
aCumulative ARR for Years 0−2 and Years 3−6.4,5,22,23,27
ARR, annualized relapse rate; CARE-MS, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; CDW, 
confirmed disability worsening; EDSS, Expanded Disability Status Scale; Gd, gadolinium; MRI, magnetic resonance 
imaging; NEDA, no evidence of disease activity.
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Furthermore, most patients had no new nonen-
hancing T1 hypointense lesions (range over Years 
2−6: 82−93%).22 Results were similar in 
CARE-MS II: 72% of patients were free of MRI 
disease activity in Year 2, and this proportion 
remained essentially unchanged in Years 3−6 
(68−70%); 91% were free of Gd-enhancing 
lesions on their Year 2 scan, remaining similarly 
high in Years 3−6 (87−91%). Annually in Years 
2−6, 86−93% had no new nonenhancing T1 
hypointense lesions.23
Data from the 10-year cohort of CAMMS223 
confirmed that alemtuzumab is highly effective at 
reducing Gd-enhancing lesion activity. At 
CAMMS223 baseline, Gd-enhancing lesions 
were present in 100% of patients, reflecting the 
study inclusion criteria. After alemtuzumab 
treatment, only 8.3% of patients had 
Gd-enhancing lesions upon entry into the 
CARE-MS extension (roughly Year 5 of follow 
up), with 5.6%, 13.0%, and 5.5% of patients hav-
ing Gd-enhancing lesions in the first, second, and 
third years of the CARE-MS extension study, 
respectively.24 Other MRI outcomes are not yet 
reported for this cohort.
No evidence of disease activity (NEDA)
NEDA (freedom from relapses, 6-month CDW, 
new Gd-enhancing lesions, and new/enlarging T2 
hyperintense lesions) is a composite endpoint that 
has come into use in recent years as a high stand-
ard for DMT efficacy.25 The proportion of alem-
tuzumab-treated patients achieving NEDA was 
consistent in each year of the extension through 6 
Figure 2. (a, b) The 6-month CDW and (c, d) 6-month CDI through 6 years in patients from CARE-MS I and II.4,5 
Number at risk is the number of patients who remained on study and who had yet to experience CDW. For CDI 
analyses, number at risk is the number of patients with baseline EDSS of ⩾2.0, who remained on study, and 
who had yet to experience CDI.
CARE-MS, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; CDI, confirmed disability improvement; 
CDW, confirmed disability worsening; EDSS, Expanded Disability Status Score
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years. Of patients from CARE-MS I, most 
achieved annual NEDA: Year 2, 68%; Year 3, 
62%; Year 4, 60%; Year 5, 62%; Year 6, 57%.26 
Results were similar for CARE-MS II (Year 2, 
58%; Year 3, 53%; Year 4, 55%; Year 5, 58%; 
Year 6, 60%).27
Brain volume loss (BVL)
Brain atrophy, as measured by BVL, is a concomi-
tant of physiologic aging. The average rate of 
annual BVL in healthy adults is age-dependent and 
heterogeneous among different tissue compart-
ments; annual brain parenchymal loss ranges from 
−0.20% at age 35 to −0.52% at age 75.28 Pathologic 
BVL occurs very early in the MS disease course 
and is predictive of disability and cognitive impair-
ment.29–31 In the alemtuzumab core and extension 
studies, BVL was derived from the change from 
baseline in brain parenchymal fraction, calculated 
from proton density/T2-weighted dual-echo 
images. Median yearly BVL progressively decreased 
over 2 years in alemtuzumab-treated patients from 
CARE-MS I and remained low in Years 3−6 
(range, −0.14 to −0.20%); similar results were 
observed in CARE-MS II (median yearly BVL in 
Years 3−6 range, −0.07 to −0.19%; Figure 3).32
Quality of life (QoL)
QoL assessments are an important complement 
to clinical and MRI data as they provide a meas-
ure of therapeutic effectiveness from the patient’s 
perspective.33 Overall, three validated instru-
ments were used to assess QoL during alemtu-
zumab studies: the Functional Assessment of 
Multiple Sclerosis (FAMS), a questionnaire spe-
cific to MS that assesses mobility, symptoms, 
emotional wellbeing, general contentment, think-
ing, fatigue, and family/social wellbeing; the 
36-Item Short-Form Survey (SF-36), which is 
summarized into mental and physical component 
summary (MCS resp. PCS) scores; and the 
European QoL 5 Dimension (EQ-5D) visual 
analog scale, which is a single-question rating 
from 0–100. In all three questionnaires, a higher 
score indicates better functioning.34–36
Alemtuzumab significantly improved QoL over 2 
years during both core CARE-MS studies com-
pared with baseline and with SC IFNβ-1a. Gains 
in QoL measures paralleled clinical and radiologic 
benefits. Analyses over 6 years of follow up have 
been reported for CARE-MS II. At the end of the 
randomized, controlled CARE-MS II trial (Year 
2), alemtuzumab patients had significant improve-
ments from baseline on FAMS [change from 
baseline at Year 2, 6.20 (95% confidence interval 
(CI): 3.69–8.71)], SF-36 MCS [2.07 (95% CI: 
1.03–3.11)], SF-36 PCS [2.51 (95% CI: 1.66–
3.36)], and EQ-5D visual analog score [4.29 
(95% CI: 2.51–6.08)].37 At Year 6, CARE-MS II 
alemtuzumab patients maintained statistically sig-
nificant improvements from baseline on FAMS 
[change from core study baseline, 3.16 (95% CI: 
0.07–6.25)], SF-36 MCS [1.58 (95% CI: 0.35–
2.82)], and EQ-5D [3.16 (95% CI: 0.93–5.38)], 
and nonsignificant improvements on SF-36 PCS 
[1.0 (95% CI: –0.03–2.03)].38
The clinical meaningfulness of improvements in 
QoL and their link to disability outcomes was 
Figure 3. Median annual change in brain volume, measured by BPF, in alemtuzumab-treated patients 
enrolled in the extension from CARE-MS I (a) or II (b).32
BPF, brain parenchymal fraction; CARE-MS, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; Y, year.
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demonstrated in a 5-year analysis in patients who 
did or did not experience 6-month CDI. Mean 
QoL improvements from baseline were signifi-
cantly greater in patients who achieved CDI ver-
sus those who did not in Years 2, 3, 4, and 5 for 
FAMS, EQ-5D visual analog scale, and SF-36 
PCS, and in Year 5 for SF-36 MCS (Figure 4).39
Safety in long-term clinical trials and in 
real-world experience
Infusion-associated reactions (IARs)
The most common AEs with alemtuzumab are 
IARs, which are mostly mild-to-moderate, and 
most commonly consist of rash, headache, 
pyrexia, urticaria, and nausea.40,41 In the pooled 
CARE-MS studies (n = 811), the incidence of 
IARs decreased with successive courses of alem-
tuzumab (courses 1−5: 85%, 69%, 65%, 63%, 
and 46%, respectively). IARs are manageable 
with appropriate pretreatment using methylpred-
nisolone, symptomatic treatment during and after 
infusion, and infusion rate adjustment. IARs are 
not increased by modest changes in the infusion 
routine (i.e. administration on nonconsecutive 
days).42 In the clinical trials, a serious AE was 
defined as fatal or life-threatening; requiring or 
prolonging hospitalization; causing persistent or 
significant disability/incapacity or congenital 
anomaly; or requiring intervention to prevent per-
manent impairment or damage. Serious IARs 
occurred in ⩽2% of patients during each course.40
Infections
Although infections during the CARE-MS core 
studies were observed more frequently with alem-
tuzumab than with the active comparator, SC 
IFNβ-1a,1,3 the incidence of infection was highest 
after the first treatment course and subsequently 
declined. In CARE-MS I, incidence was 56.1% 
in Year 1, declining to 35.5% in Year 6. In 
CARE-MS II, infection incidence was 63.2% in 
Year 1 and declined to 43.4% in Year 6. Rates of 
serious infections were low in each year (<2% in 
CARE-MS I and <3% in CARE-MS II).4,5
After a protocol amendment in the core studies, 
acyclovir was given during the first month after 
each course of alemtuzumab as prophylaxis for 
herpetic infections. Herpetic infection data are 
Figure 4. Change from baseline in FAMS score (a, b) and SF-36 PCS (c,d) score in CARE-MS I and II patients 
with and without 6-month CDI.39,45
*Significant change from baseline, p < 0.05; †Significant difference between groups, p < 0.05.
CARE-MS, Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; CDI, confirmed disability improvement; 
FAMS, Functional Assessment of Multiple Sclerosis; PCS, Physical Component Summary; SF-36, 36-Item Short-Form 
Survey; Y, year.
Therapeutic Advances in Neurological Disorders 10(10)
350 journals.sagepub.com/home/tan
available for the pooled CARE-MS core studies 
and the first 2 years of the extension. In Years 
1−4, herpes simplex incidence was 9.0%, 5.4%, 
3.1%, and 2.5%, respectively, and herpes zoster 
incidence was 2.1%, 2.7%, 3.4%, and 2.2%, 
respectively.43
Outside the clinical trials, several case studies 
have reported opportunistic infections after alem-
tuzumab treatment. Overall, two patients devel-
oped cytomegalovirus disease ⩽1 month after the 
initial 5-day course and recovered fully with treat-
ment.44 Among 66 patients who received a total 
of 100 courses of alemtuzumab during 1 year at a 
tertiary center in Germany, 3 developed acute 
acalculous cholecystitis.45 All three patients 
recovered rapidly following treatment. In the 
United States (US), a rare pathogen, Nocardia 
beijingensis, was isolated from a patient diagnosed 
with sepsis secondary to pneumonia 6 weeks after 
completing the first course of alemtuzumab; the 
patient responded well to treatment.46 Finally, 
several cases of Listeria monocytogenes infection 
have been reported. In one case, the patient had 
recent exposure to foods including smoked sau-
sage and soft cheese and developed Listeria sep-
ticemia after the initial alemtuzumab infusion.47 
Additionally, three cases of Listeria meningitis 
occurred shortly after the first course of alemtu-
zumab and were successfully managed, although 
one patient had severe sequelae.48,49
Postmarketing surveillance data on opportunistic 
infections, gathered by the manufacturer on the 
~13,000 patients worldwide who have been treated 
with alemtuzumab for MS, have been reported.50 
The most commonly reported opportunistic infec-
tion is L. monocytogenes (estimated frequency: 
0.26%), followed by cytomegalovirus (estimated 
frequency: 0.13%). Product labeling now recom-
mends that patients avoid or adequately heat 
foods that are potential sources of Listeria in a 
period of 2 weeks before and 2 months after alem-
tuzumab infusion. There have been no medically 
confirmed cases of progressive multifocal leu-
koencephalopathy (PML) in MS without relevant 
pretreatments (natalizumab-associated PML).
Autoimmune events
Alemtuzumab has been associated with autoim-
mune AEs due, it is hypothesized, to its mecha-
nism of action. These AEs, mainly comprising 
thyroid disorders and, less frequently, ITP and 
nephropathies, can occur early post-treatment; 
however, onset is more often delayed a few years 
after the last infusion.51 The clinical development 
program for alemtuzumab included a number of 
steps to mitigate risks associated with these AEs; 
protocol-defined laboratory monitoring measures 
and physician and patient education facilitated 
early detection and effective management of the 
conditions. These measures have also been imple-
mented in clinical practice as part of the Risk 
Evaluation and Mitigation Strategy (US) and 
Risk Management Plan (Europe), providing for 
monitoring beginning prior to treatment and con-
tinuing for 48 months after the last dose of alem-
tuzumab, or longer if clinically indicated.8,10
Among pooled CARE-MS patients who received 
alemtuzumab 12 mg (n = 811), the cumulative 
incidence of thyroid events was 42% over 6 
years.52 First onset of the majority (82%) of thy-
roid AEs occurred within 2 years of the last alem-
tuzumab treatment course. For events related to 
hyperthyroidism, treatments included anti-thy-
roid medications, radioiodine ablation, or thy-
roidectomy (combined with thyroid hormone 
replacement therapy); hypothyroid conditions 
were treated with thyroid hormone replacement 
therapy. In patients with thyroid AEs, 20.7% of 
cases resolved spontaneously (i.e. without treat-
ment); of those who were treated according to site 
protocols, 79.0% (n = 271) received conven-
tional oral medications, 9.0% (n = 31) had iodine 
ablation, and 8.5% (n = 29) underwent thyroid-
ectomy (some received more than one treatment). 
Few serious thyroid AEs were reported; the inci-
dence of serious thyroid AEs peaked at Year 3 
(3.1%) and subsequently declined.
Data on ITP in the clinical development program 
are available with a December 2014 cutoff date, 
representing roughly 5 years of total follow up for 
the CARE-MS studies and 8 years for 
CAMMS223.53 The cumulative incidence of ITP 
was 2.3% (n = 34 of 1486) in all alemtuzumab-
treated patients, and 2.0% (n = 24 of 1217) in 
those treated with the 12-mg dose. Across the 
clinical development program, most of the 34 
patients who developed ITP received only first-
line therapy, consisting of corticosteroids with or 
without intravenous immunoglobulin or platelet 
infusion. A total of seven patients required sec-
ond-line therapy with rituximab, and one patient 
was treated with splenectomy according to the 
site treatment protocol. All patients had a durable 
remission from ITP after treatment (or spontane-
ously without treatment in two cases). Only one 
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patient had another episode of ITP; her initial 
episode occurred 16 months after the last alemtu-
zumab dose, and then she experienced a second 
episode 7 years later that was responsive to treat-
ment with corticosteroids.
Postmarketing surveillance has found the inci-
dence of autoimmune cytopenias to be generally 
lower than in clinical trials for ITP (postmarket-
ing estimated frequency: 0.58%), hemolytic 
anemia (0.05%), and pancytopenia (0.10%).50 
Neutropenia in the postmarketing setting (0.48%) 
was higher than that of serious neutropenia in the 
clinical trials (0.2%), but lower than that of all 
neutropenia events in the clinical trials (1.7%).
In the clinical development program, four cases 
of autoimmune nephropathy occurred among 
1486 patients exposed to alemtuzumab, giving a 
cumulative incidence of 0.27%. Overall, two 
cases were membranous glomerulonephritis, one 
case was glomerulonephritis with anti-glomerular 
basement membrane (GBM) antibodies, and one 
was anti-GBM disease. The patients with anti-
GBM disease or with membranous glomerulone-
phritis with anti-GBM antibodies were treated 
with plasmapheresis, cyclophosphamide, and 
steroids. The patients with membranous glomer-
ulonephritis were treated with angiotensin-con-
verting enzyme inhibitors and diuretics. A total of 
three patients entered remission and recovered 
renal function, whereas the fourth had persistent 
proteinuria at the time of reporting; however, this 
patient’s membranous glomerulonephritis was 
resolved.54 In postmarketing surveillance, the 
estimated frequency of nephropathy is 0.13%.50
A single case report was published on a patient 
who developed type 1 diabetes 29 months after 
receiving the second course of alemtuzumab.55 
The patient had a family history of type 1 diabetes 
and was prediabetic before initiating alemtu-
zumab. This case highlights the importance of a 
patient’s susceptibility to other autoimmune con-
ditions as a component of risk assessment.
Importantly, in controlled studies, alemtuzumab 
efficacy and patient-reported QoL were unaf-
fected by the occurrence of autoimmune AEs. 
Subgroup analyses performed on core study data 
showed that at Year 2, there were no significant 
differences in QoL improvements in alemtu-
zumab-treated patients with or without thyroid 
AEs,56 or with or without any autoimmune AE.57 
In an analysis of 4-year data from the CARE-MS 
studies, ARR and the proportion of patients free 
of CDW were similar in subgroups of patients 
who had and had not experienced a thyroid AE.58
Evolving understanding of alemtuzumab 
mechanism of action
Alemtuzumab selectively targets CD52, an anti-
gen expressed highly on the surface of circulating 
T and B lymphocytes, cells that contribute 
directly to the underlying pathophysiology of MS. 
B-cells serve as highly specific antigen-presenting 
cells and provide costimulation to autoreactive 
T-cells, and antibodies contribute to demyelina-
tion and complement fixation.59,60 T-cells medi-
ate damage to myelin and nerves.61,62 Regulatory 
T-cells (Tregs) inhibit autoreactive T-cells through 
cell–cell interactions and the secretion of anti-
inflammatory cytokines.63,64 In patients with MS, 
Treg impairment enables activation of CD4+ 
T-cells including the T-helper (Th) 17 and Th1 
cell subsets; in turn, Th17 and Th1 cells activate 
microglia to assume an inflammatory and neuro-
toxic phenotype.65,66
Alemtuzumab depletes circulating T and B lym-
phocytes through antibody-dependent, cell- and 
complement-mediated cytotoxicity,67,68 with the 
lowest cell counts observed at the first post-base-
line assessment (1 month after treatment in 
CARE-MS I and II). Lymphocyte depletion is 
followed by a distinct pattern of T- and B-cell 
repopulation that begins within weeks, with B-cell 
counts returning to baseline levels within 6 
months, whereas T-cell counts rise more slowly, 
generally approaching the lower limits of normal 
by 12 months.10,69 A recent multicenter follow up 
of 29 patients also found that the percentage of 
CD4+ T-cells (as a proportion of total lympho-
cytes) in the periphery did not return to baseline 
levels until 48 months later.70 There was no 
cumulative reduction in CD4+, CD8+, and 
CD19+ repopulation capacity with successive 
alemtuzumab courses.71
Recent results in an animal model suggested 
that alemtuzumab efficacy is related to the level 
of CD4+ T-cell depletion; however, the pattern 
of lymphocyte repopulation is key to the pro-
posed alemtuzumab mechanism of action.10,72 
Repopulation results in a relative increase of 
cells with memory and regulatory phenotypes 
and a decrease in cells with a proinflammatory 
signature.73,74 Th17 and Th1 cells remained 
low through at least 48 months following 
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alemtuzumab treatment, with a concomitant 
decrease in proinflammatory cytokines associ-
ated with these cell types.70
Finally, although alemtuzumab has a minimal or 
transient effect on circulating monocytes, eosin-
ophils, and basophils,69 recent data indicate that 
it may promote an immunoregulatory environ-
ment through an impact on other innate immune 
cells (e.g. dendritic cells) that play a role in MS. 
In patients with MS, dendritic cells are function-
ally abnormal, express upregulated levels of 
costimulatory molecules and proinflammatory 
cytokines, and stimulate proinflammatory 
cytokine secretion by effector T-cells.65,75,76 
They may also interact with natural killer (NK) 
cells to induce selective CD56bright NK cell 
expansion.65,66,77 The CD56bright NK population 
exerts regulatory effects on autoreactive T-cells 
via cytotoxicity or suppression of T-cell prolif-
eration.78 Alemtuzumab reduced the propor-
tions of circulating dendritic cells (conventional 
and plasmacytoid subsets), and expanded the 
CD56bright NK cell population, although the 
cytolytic function of NK cells was not altered.41,79 
Together, the effects of alemtuzumab on T and 
B-cells, its effects on subsets of innate immune 
cells important in RRMS pathophysiology, and 
its overall rebalancing of the immune system 
may underlie its durable clinical effects (includ-
ing disability improvement and slowing of BVL) 
and reduce the potential for relapse, ultimately 
delaying disease progression.
Benefit–risk considerations for 
alemtuzumab use
A notable benefit of alemtuzumab therapy is 
improvement in preexisting disability, which may 
have a positive impact on long-term prognosis. 
Other important benefits are a reduction in the 
rate of BVL, achievement of annual NEDA, 
improvements in QoL, and a potentially low risk 
of progressing to SPMS.4,5,21,32,38 During the 
phase II and III core studies and continuing 
throughout the extension, these benefits were 
achieved in the absence of continuous treatment 
with regular, repeated dosing on a daily, every 
other day, thrice weekly, weekly, every other 
week, monthly, or every 6 month schedule. 
Furthermore, the majority of patients did not 
receive additional alemtuzumab or any other 
DMT after the initial 2-course regimen. This rel-
ative freedom from therapy, together with long-
lasting clinical improvement or stability, 
comprehensive education for clinicians, patient 
education, and rigorous safety monitoring, may 
represent a shift in the standard by which thera-
peutic efficacy is judged.
Considerations of the potential benefits of alem-
tuzumab treatment must also be balanced by 
potential risks. The risks associated with alemtu-
zumab are well characterized and detectable with 
vigilant monitoring and, when identified early, 
are generally manageable. Follow up of up to 10 
years confirmed that the risk for autoimmune 
AEs decreases substantially in the fourth year 
after the last alemtuzumab dose. This observation 
supports the rationale for the timeframe of the 
safety monitoring program (4 years after the last 
alemtuzumab dose, i.e. a minimum of 5 years in 
patients who require only two courses of alemtu-
zumab), which was effective in detecting autoim-
mune AEs during the clinical trials. In the case of 
thyroid autoimmune events, few were serious. 
Armed with a well characterized safety profile, a 
thorough education program, and careful moni-
toring procedures, clinicians are able to maximize 
benefits while minimizing treatment risks.
Alemtuzumab is a highly efficacious DMT that 
offers a new treatment principle for RRMS, but 
its pharmacodynamic effects are not reversible in 
the short term, and it may require both treatment 
courses before full clinical benefit is observed. 
The strong evidence from the clinical develop-
ment program suggests it should be used rela-
tively early in the disease course; due to its 
irreversible effects in the short term and potential 
side effects, benefit–risk ratio has to be evaluated 
individually in the context of other available 
treatments.
Experience with switching to alemtuzumab 
from other DMTs
The most comprehensive available data set on 
outcomes of switching therapy to alemtuzumab 
comes from the CARE-MS patients who were 
randomized to SC IFNβ-1a in the core studies 
and, on entering the extension study, switched 
therapy to two courses of alemtuzumab.80,81 The 
protocol did not specify a washout period, but 
patients had ⩽2 months after discontinuing SC 
IFNβ-1a to receive alemtuzumab. Over 4 years of 
follow up after alemtuzumab initiation, ARR fell 
by approximately 70% compared with SC 
IFNβ-1a treatment, 81% (CARE-MS I) and 80% 
(CARE-MS II) of patients remained free of 
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6-month CDW, and 27% and 22% achieved 
6-month CDI, respectively. The rate of BVL 
slowed after alemtuzumab initiation.82 No new 
safety signals arose in this cohort.
Data documenting outcomes in patients who 
switched to alemtuzumab from other DMTs are 
limited. An observational, multicenter study 
reported on 36 patients who initiated alemtu-
zumab after having inflammatory disease activity 
while on fingolimod therapy. Median fingolimod 
washout period was 6 weeks. Overall, nine of 
these patients experienced significant disease 
activity in the 12 months following alemtuzumab 
infusion.83 A total of eight patients were charac-
terized by ⩾1 clinical relapse and radiologic dis-
ease activity, with the remaining patient by 
radiologic disease activity alone. All nine patients 
subsequently received the second course of alem-
tuzumab, after which eight patients were relapse-
free (mean 6-month follow up). These data 
highlight the importance of administering the full 
treatment of two courses. The authors proposed 
that prolonged sequestration of autoreactive lym-
phocytes following fingolimod withdrawal 
shielded the cells from the biologic effect of alem-
tuzumab and that subsequent lymphocyte out-
flow elicited disease reactivation.83
In another observational study, patients (n = 
16) who had responded to natalizumab, but dis-
continued because of the risk of PML, initiated 
alemtuzumab after a median washout of 70 
days.84 Available brain MRI data at 6 and 12 
months after alemtuzumab administration 
showed no signs of disease activity. Clinical eval-
uation at 6 and 12 months indicated stability, 
with no relapses or increase in EDSS. None of 
the patients experienced severe side effects or 
developed PML.
A case report was published in which two 
patients presented with apparent severe exacer-
bation of MS symptoms after alemtuzumab 
infusion; it was undetermined whether these 
were actual MS relapses or secondary autoim-
munity directed toward the central nervous sys-
tem. Both patients had ongoing disease activity 
despite prior treatments (most recently dimethyl 
fumarate and fingolimod) before switching to 
alemtuzumab. These cases were successfully 
managed with plasma exchange followed by 
rituximab administration.85 The authors pro-
posed that these cases were B-cell-driven, given 
the effectiveness of plasma exchange plus 
rituximab, and that the timing of symptom onset 
coincided with B-cell repopulation post-alemtu-
zumab; however, whether these symptoms 
reflected MS exacerbation or a secondary auto-
immunity was undetermined.
A second case report noted increased disease 
activity after switching to alemtuzumab in a 
patient with a treatment history of glatiramer ace-
tate, fingolimod, natalizumab, and dimethyl 
fumarate (previous switches had been made due 
to disease progression or John Cunningham virus 
positivity).86 After 4 months from alemtuzumab 
initiation, the patient experienced unilateral dys-
esthesia and intermittent ataxia; brain MRI dis-
closed a tumefactive demyelinating lesion. The 
patient recovered spontaneously over 3 months.
Real-world studies
Robust real-world studies are needed following 
marketing authorization to assess the short-and 
long-term effectiveness of DMTs in the popula-
tion of patients with well characterized comor-
bidities and comedication who are eligible to 
receive treatment in clinical practice, and for 
whom patient monitoring is not constrained by 
protocol.87,88 Although more than 1400 patients 
have been treated with alemtuzumab in con-
trolled clinical trials, data on the use of alemtu-
zumab and outcomes of treatment under clinical 
practice conditions will provide valuable addi-
tional information on the real-world efficacy and 
safety of this agent. Real-world data to date are 
limited, given that marketing approval was 
granted only 3 years ago in Europe and 2 years 
ago in the US.
A recent, observational study of the MSBase 
cohort provided insights into comparative effec-
tiveness of alemtuzumab and other DMTs for 
patients with RRMS. Of 15,783 patients with 
MS, 4332 received either alemtuzumab (n = 
189), IFNβ (n = 2155), fingolimod (n = 828), or 
natalizumab (n = 1160) between 1994 and 
2016.89 Patients had a mean disease duration of 
roughly 3 years, with an EDSS score of 3.0 and 
approximately two relapses in the 12 months before 
baseline. In an analysis of propensity score-matched 
patients, ARR with alemtuzumab was lower than 
with IFNβ [0.19 (95% CI, 0.14–0.23) versus 0.53 
(0.46–0.61), p < 0.0001] or fingolimod [0.15 
(0.10–0.20) versus 0.34 (0.26–0.41), p < 0.0001], 
and similar to ARR with natalizumab [0.20 (0.14–
0.26) versus 0.19 (0.15–0.23), p = 0.78]. 
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Probabilities of disability accumulation were sim-
ilar among all four therapies.89
In a chart review study in the UK, 100 patients 
with aggressive RRMS and a poor prognosis were 
treated with alemtuzumab since 2000 and fol-
lowed up for a mean of 6.1 years.90 Alemtuzumab 
use was off-label prior to its approval for RRMS 
and, until 2006, the dosage given was higher (24–
30 mg/day) than the currently approved dosage 
(12 mg/day). ARR decreased from 2.1 pretreat-
ment to 0.2 post-treatment; a low ARR was main-
tained up to 8 years. Mean EDSS change from 
the pretreatment level was +0.14, 27% of patients 
experienced CDW, and 25% had CDI. The 
alemtuzumab safety profile in this cohort was 
consistent with the clinical trial experience, with 
the exceptions of five cases of cervical dysplasia 
and three cases of monoclonal gammopathy of 
uncertain significance.
TREAT-MS is an ongoing, open-label, uncon-
trolled, multicenter, prospective, noninterven-
tional study documenting the alemtuzumab 
experience in approximately 3200 RRMS patients 
from 400 sites in Germany.91 In this study, the 
MS software-based documentation system, 
MSDS3D, is used to guide physicians through 
the complex processes of diagnosis and treat-
ment.92,93 Patients complete questionnaires to 
evaluate satisfaction with treatment, cognition, 
state of health, health-related QoL, and ability to 
work. In addition, physicians provide an assess-
ment of patients’ state of health and disease-
related QoL. Safety data are also being collected. 
Preliminary analyses of baseline characteristics of 
the enrolled population showed that TREAT-MS 
patients have more severe MS disease than 
patients in the phase II and III studies, with a 
longer average disease duration, higher EDSS 
score, and more relapse activity. Thus, this cohort 
will provide new insights on alemtuzumab effi-
cacy in more severe MS.
In a real-world, ongoing, observational cohort of 
250 patients who received alemtuzumab at a sin-
gle MS treatment center in the US, interim anal-
ysis showed that during 4–12-month follow up, 
there was a marked absence of clinical worsen-
ing.94 IARs were common but generally mild, 
and no cases of PML were reported. The major-
ity (n = 200) of patients in this cohort had dis-
continued natalizumab before initiating 
alemtuzumab. It is possible that alemtuzumab 
helped attenuate disease re-emergence after 
natalizumab discontinuation, although the lack 
of a control arm precludes this conclusion. 
During the 6 months following natalizumab dis-
continuation and alemtuzumab initiation, none 
of the patients relapsed; EDSS score improved 
in 69/162 (43%) patients and worsened in 2/162 
(1%).94
Outlook
In addition to the aforementioned completed and 
ongoing real-world studies, longer-term data on 
outcomes in patients from the clinical develop-
ment program are being collected. Patients com-
pleting the CARE-MS extension study are being 
followed up for an additional 5 years in the 
TOPAZ study [ClinicalTrials.gov identifier: 
NCT02255656].95 At the conclusion of TOPAZ, 
the CARE-MS cohort will have been followed up 
for a total of 11 years, and patients from 
CAMMS223 for 15 years.
TOPAZ is accompanied by many other phase IV 
studies currently being conducted across Europe 
and the Americas, focusing on areas including 
infusion management (EMERALD), QoL and 
other patient-reported outcomes (LEMQoL, 
PRO-ACT, LemVida, REALITY), safety 
(PASS), and cognition (LemCOG). In addition, 
an exploratory, independent phase IV study has 
been initiated to identify markers for treatment 
response and autoimmune AE risk stratification. 
This analysis of immunologic parameters will 
help to improve patient selection and elucidate 
the mechanism of action of alemtuzumab.96 Thus 
the knowledge base about alemtuzumab treat-
ment of RRMS will continue to grow as data 
emerge on longer-term efficacy and safety (>6 
years), mechanism of action, patient perspectives, 
and other nontraditional endpoints.
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